ArticleThrombosis journal2025
Factors influencing antithrombin activity following supplementation in sepsis-associated disseminated intravascular coagulation.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntithrombin, a key regulator of the coagulation cascade, is often decreased in patients with sepsis-associated disseminated intravascular coagulation (DIC). Antithrombin is commonly supplemented when activity levels fall to 70% or below in Japan. While there is considerable interindividual variability in antithrombin activity following treatment, the factors contributing to this variability remain unclear. This study aims to identify the determinants of post-treatment antithrombin activity levels and to investigate the potential association between antithrombin activity and bleeding risk.
methodsWe conducted a retrospective analysis using data from the post-marketing surveillance of antithrombin concentrate in patients with sepsis-associated DIC. Changes in antithrombin activity were calculated as: (Day 1 activity - baseline activity [%]) divided by the daily dose (international units [IU] per kilogram of body weight). Logistic regression analysis was employed to identify factors associated with changes in antithrombin activity following supplementation and factors related to bleeding risk. Additionally, Kaplan-Meier survival curves were used to examine the relationship between antithrombin activity and 28-day survival outcomes.
resultsA total of 1,524 patients were included in the analysis. The median baseline antithrombin activity was 49%, which increased to 74% on day 1 post-treatment. The mean change in antithrombin activity was 0.99% /IU/kg and followed a normal distribution. The SOFA score ≥ 13 (p = 0.035) and FDP score ≥ 3 (≥ 25μg/mL), part of the JAAM DIC score, (p = 0.016) were significantly associated with lower antithrombin activity increase. Patients achieving ≥ 1% /IU/kg increase showed a higher 28-day survival rate (relative risk: 0.72, p = 0.004). No significant association was found between antithrombin doses or activity changes and bleeding risk.
conclusionA higher SOFA score and FDP level were associated with a smaller increase in post-treatment antithrombin activity. There was no clear association between antithrombin doses and bleeding risk. The present study suggests the necessity of individualized dosing beyond weight-based regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.